Juha Ellmén

567 total citations
23 papers, 455 citations indexed

About

Juha Ellmén is a scholar working on Neurology, Oncology and Epidemiology. According to data from OpenAlex, Juha Ellmén has authored 23 papers receiving a total of 455 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Neurology, 6 papers in Oncology and 6 papers in Epidemiology. Recurrent topics in Juha Ellmén's work include Parkinson's Disease Mechanisms and Treatments (10 papers), Estrogen and related hormone effects (6 papers) and Neurological disorders and treatments (4 papers). Juha Ellmén is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (10 papers), Estrogen and related hormone effects (6 papers) and Neurological disorders and treatments (4 papers). Juha Ellmén collaborates with scholars based in Finland, United Kingdom and Russia. Juha Ellmén's co-authors include M. Gershanovich, Mikko Kuoppamäki, Mikko Vahteristo, Jouni Vuorinen, Daniel F. Hayes, Anu Partanen, D F Hayes, T. Tominaga, M. Kaufmann and Seppo Pyrhönen and has published in prestigious journals such as Neurology, JNCI Journal of the National Cancer Institute and Movement Disorders.

In The Last Decade

Juha Ellmén

22 papers receiving 441 citations

Peers

Juha Ellmén
Yanqiang Wang China
Yoshio Izumi Japan
John Fernandes Netherlands
Zhiyuan Zhao China
Markus A. Schramm Germany
H Yano Japan
Mahmoud Kassem United States
L Horváth Hungary
Shouping Gong China
Yanqiang Wang China
Juha Ellmén
Citations per year, relative to Juha Ellmén Juha Ellmén (= 1×) peers Yanqiang Wang

Countries citing papers authored by Juha Ellmén

Since Specialization
Citations

This map shows the geographic impact of Juha Ellmén's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juha Ellmén with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juha Ellmén more than expected).

Fields of papers citing papers by Juha Ellmén

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juha Ellmén. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juha Ellmén. The network helps show where Juha Ellmén may publish in the future.

Co-authorship network of co-authors of Juha Ellmén

This figure shows the co-authorship network connecting the top 25 collaborators of Juha Ellmén. A scholar is included among the top collaborators of Juha Ellmén based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juha Ellmén. Juha Ellmén is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sjöstedt, Noora, Mikko Vahteristo, Juha Ellmén, et al.. (2022). Effect of Carbidopa Dose on Levodopa Pharmacokinetics With and Without Catechol-O-Methyltransferase Inhibition in Healthy Subjects. European Journal of Drug Metabolism and Pharmacokinetics. 48(1). 23–34. 1 indexed citations
2.
Kivikko, Matti, Mikko Kuoppamäki, Lauri Soinne, et al.. (2015). Oral Levosimendan Increases Cerebral Blood Flow Velocities in Patients with a History of Stroke or Transient Ischemic Attack: A Pilot Safety Study. Current Therapeutic Research. 77. 46–51. 12 indexed citations
3.
Korhonen, Pasi, Mikko Kuoppamäki, Fabian Hoti, et al.. (2015). Entacapone and Prostate Cancer Risk in Patients With Parkinson's Disease. Movement Disorders. 30(5). 724–728. 7 indexed citations
4.
Kuoppamäki, Mikko, Mikko Vahteristo, Juha Ellmén, & Karl Kieburtz. (2014). Pooled analysis of phase III with entacapone in Parkinson's disease. Acta Neurologica Scandinavica. 130(4). 239–247. 13 indexed citations
5.
6.
Vahteristo, Mikko, et al.. (2011). The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations. European Journal of Clinical Pharmacology. 68(3). 281–289. 22 indexed citations
7.
Kuoppamäki, Mikko, et al.. (2010). Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa. International Journal of Clinical Pharmacology and Therapeutics. 48(11). 756–760. 4 indexed citations
8.
Kuoppamäki, Mikko, Reijo J. Marttila, Valtteri Kaasinen, et al.. (2009). Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily. European Journal of Clinical Pharmacology. 65(5). 443–455. 68 indexed citations
9.
Polo, Olli, et al.. (2007). Entacapone Prolongs the Reduction of PLM by Levodopa/Carbidopa in Restless Legs Syndrome. Clinical Neuropharmacology. 30(6). 335–344. 10 indexed citations
10.
11.
Ellmén, Juha, et al.. (2003). Estrogenic Effects of Toremifene and Tamoxifen in Postmenopausal Breast Cancer Patients. Breast Cancer Research and Treatment. 82(2). 103–111. 50 indexed citations
12.
Pyrhönen, Seppo, Juha Ellmén, Jouni Vuorinen, et al.. (1999). Meta‐analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Research and Treatment. 56(2). 131–141. 84 indexed citations
13.
Mäenpää, Juhani, et al.. (1999). Re: Effects of the Antiestrogens Tamoxifen, Toremifene, and ICI 182,780 on Endometrial Cancer Growth. JNCI Journal of the National Cancer Institute. 91(11). 972–973. 8 indexed citations
14.
Gershanovich, M., et al.. (1997). High-dose toremifene in advanced renal-cell carcinoma. Cancer Chemotherapy and Pharmacology. 39(6). 547–551. 11 indexed citations
15.
Gershanovich, M., et al.. (1997). A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Breast Cancer Research and Treatment. 45(3). 251–262. 69 indexed citations
16.
Gershanovich, M., Daniel F. Hayes, Juha Ellmén, & Jouni Vuorinen. (1997). High-dose toremifene vs tamoxifen in postmenopausal advanced breast cancer.. PubMed. 11(5 Suppl 4). 29–36. 15 indexed citations
17.
Salomaa, Eija‐Riitta, Kari Liippo, Juha Ellmén, & Janne Komi. (1996). Ifosfamide combined with toremifene in the treatment of non-small cell lung cancer. Lung Cancer. 16(1). 75–80. 2 indexed citations
18.
Liippo, Kari, Juha Ellmén, E Vänttinen, & Markku Anttila. (1996). Toremifene concentration and multidrug resistance in lung tumors. Cancer Chemotherapy and Pharmacology. 39(3). 212–216. 6 indexed citations
19.
Ellmén, Juha, O V Renkonen, M Anttila, & Heikki Peltola. (1991). Antibiotic Concentrations in Liquor Compared to the Minimal Inhibitory Concentrations of Isolates in Paediatric Bacterial Meningitis. Chemotherapy. 37(1). 1–5. 3 indexed citations
20.
Lassus, A, Olli-Veikko Renkonen, & Juha Ellmén. (1988). Fleroxacin versus standard therapy in gonococcal urethritis. Journal of Antimicrobial Chemotherapy. 22(Supplement_D). 223–225. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yanqiang Wang Breakdown of academic impact, for papers by Yoshio Izumi Breakdown of academic impact, for papers by John Fernandes Breakdown of academic impact, for papers by Zhiyuan Zhao Breakdown of academic impact, for papers by Markus A. Schramm Breakdown of academic impact, for papers by H Yano Breakdown of academic impact, for papers by Mahmoud Kassem Breakdown of academic impact, for papers by L Horváth Breakdown of academic impact, for papers by Shouping Gong
Rankless by CCL
2026